Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: Novartis' Oncology Chief On Sharpening Its Competitive Advantage

Executive Summary

Novartis Oncology President Bruno Strigini talks about refining the pharma major's oncology strategy and its pipeline potential.


Related Content

Novartis Oncology Strategy: Focus On The Microenvironment
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Alcon Loses CEO And Eye Drugs After Dragging On Novartis Financials
'This Isn't The Past Novartis,' Jimenez Tells JPM Conference
Novartis's Farydak Enters EU As First-In-Class Myeloma Therapy
Aduro gets $200m as Novartis steps up immuno-oncology
Strategic Strigini and the European endeavor


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts